Best Wegovy Alternative for 2026? FDA Approves Oral Semaglutide as Patients Evaluate Compounded Telehealth Access — Direct Meds Examined as Verification Case Study
12/30/2025 08:57 PM • The FDA approved an oral semaglutide option for chronic weight management on December 22, 2025, expanding GLP-1 medication access beyond injectables. The article examines how cost-conscious patients navigate different GLP-1 access pathways—FDA-approved brand medications, compounded telehealth options, and insurance-covered treatment—while highlighting verification methods consumers use to evaluate telehealth platforms, including LegitScript certification and pharmacy disclosure transparency.
NVO - FDA approval of oral semaglutide (Wegovy pill) on December 22, 2025, with planned full U.S. launch in early January 2026. OASIS 4 trial data shows 13.6% mean weight loss, positioning the company favorably in the expanding GLP-1 market.